Deprince Race & Zollo Inc. Trims Position in Mativ Holdings, Inc. (NYSE:MATV)

Deprince Race & Zollo Inc. lessened its holdings in Mativ Holdings, Inc. (NYSE:MATV - Free Report) by 11.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 554,263 shares of the company's stock after selling 68,694 shares during the period. Deprince Race & Zollo Inc. owned about 1.02% of Mativ worth $9,400,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Wellington Management Group LLP grew its holdings in shares of Mativ by 3.8% during the fourth quarter. Wellington Management Group LLP now owns 3,583,501 shares of the company's stock worth $54,863,000 after purchasing an additional 130,362 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Mativ by 2.5% in the second quarter. Dimensional Fund Advisors LP now owns 2,154,818 shares of the company's stock valued at $36,546,000 after acquiring an additional 52,858 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Mativ by 579.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,713,790 shares of the company's stock valued at $26,238,000 after acquiring an additional 1,461,640 shares during the last quarter. Vaughan Nelson Investment Management L.P. boosted its holdings in Mativ by 12.9% in the second quarter. Vaughan Nelson Investment Management L.P. now owns 1,544,028 shares of the company's stock valued at $26,187,000 after acquiring an additional 176,600 shares during the last quarter. Finally, American Century Companies Inc. boosted its holdings in Mativ by 67.2% in the second quarter. American Century Companies Inc. now owns 749,967 shares of the company's stock valued at $12,719,000 after acquiring an additional 301,488 shares during the last quarter. Institutional investors own 94.95% of the company's stock.

Mativ Trading Down 0.6 %

MATV stock traded down $0.10 during trading on Friday, hitting $17.21. The company had a trading volume of 323,472 shares, compared to its average volume of 420,623. The business has a 50-day moving average of $17.94 and a 200-day moving average of $17.73. Mativ Holdings, Inc. has a one year low of $10.78 and a one year high of $19.96. The stock has a market cap of $935.02 million, a PE ratio of -2.85, a PEG ratio of 3.59 and a beta of 0.70. The company has a current ratio of 2.46, a quick ratio of 1.33 and a debt-to-equity ratio of 1.28.

Mativ (NYSE:MATV - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.21 by $0.13. Mativ had a positive return on equity of 5.19% and a negative net margin of 16.55%. The business had revenue of $523.80 million for the quarter, compared to analysts' expectations of $526.50 million. During the same period in the prior year, the business posted $0.51 earnings per share. Research analysts predict that Mativ Holdings, Inc. will post 0.82 earnings per share for the current fiscal year.

Mativ Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 20th. Shareholders of record on Friday, August 23rd were paid a $0.10 dividend. This represents a $0.40 annualized dividend and a yield of 2.32%. The ex-dividend date was Friday, August 23rd. Mativ's dividend payout ratio (DPR) is presently -6.62%.

About Mativ

Mativ Holdings, Inc, together with its subsidiaries, manufactures and sells specialty materials in the United States, Europe, the Asia Pacific, the Americas, and internationally. The company operates through two segments, Advanced Technical Materials and Fiber-Based Solutions. The Advanced Technical Materials manufactures and sells various engineered polymer, resin and fiber-based substrates, nets, films, adhesive tapes, and other nonwovens for the filtration, protective solutions, release liners, and healthcare end-markets.